IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 25.38

Change

0.00 (0.00)%

Market Cap

USD 0.15B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-09 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.08 (-1.39%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.03 (-1.45%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-1.57 (-1.39%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-0.84 (-0.90%)

USD 0.22B
SBIO ALPS Medical Breakthroughs ETF

-1.67 (-3.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-1.54 (-1.56%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.45 (-1.48%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-2.05 (-3.02%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-1.51 (-4.81%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

-0.94 (-1.69%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.30% 67% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.30% 67% D+ 58% F
Trailing 12 Months  
Capital Gain 37.86% 86% B+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.86% 86% B+ 78% C+
Trailing 5 Years  
Capital Gain -4.27% 48% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.27% 48% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain -2.65% 5% F 22% F
Dividend Return -2.15% 5% F 14% F
Total Return 0.49% 53% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 34.93% 14% F 29% F
Risk Adjusted Return -6.16% 5% F 18% F
Market Capitalization 0.15B 60% D- 32% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.